Evidence map›Paper›PMID 34749675›Full record

Trial reportBMC public health2021

Impact and experience of participant engagement activities in supporting dapivirine ring use among participants enrolled in the phase III MTN-020/ASPIRE study.

Morgan Garcia, Ellen Luecke, Ashley J Mayo, Rachel Scheckter, Patrick Ndase, Flavia Matovu Kiweewa, Doreen Kemigisha, Petina Musara, Leila E Mansoor, Nishanta Singh and 13 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMC public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Article
  3. Observational
  4. Article
  5. Telerehabilitation is as effective as outpatient visits in the management of early osteoarthritis knee and mechanical low backache.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2024
    Observational
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 13 institutions in 5 countries.

Morgan GarciaGlobal Health Population and Nutrition, FHI, Durham, NC, 360, USA. mgarcia@fhi360.org.
Ellen LueckeWomen's Global Health Imperative (WGHI) RTI International, Berkeley, CA, USA; ASTRA Consulting, Kensington, CA, USA.
Ashley J MayoGlobal Health Population and Nutrition, FHI, Durham, NC, 360, USA.
Rachel ScheckterGlobal Health Population and Nutrition, FHI, Durham, NC, 360, USA.
Patrick NdasePopulation Services International (PSI), 1120 19th St. NW, Washington, DC, USA.
Flavia Matovu KiweewaMakerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Kampala, Uganda.
Doreen KemigishaMakerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Kampala, Uganda.
Petina MusaraUniversity of Zimbabwe College of Health Sciences-Clinical Trials Research Centre, Harare, Zimbabwe.
Leila E MansoorCentre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.
Nishanta SinghHIV Prevention Research Unit (HPRU), South African Medical Research Council (SAMRC), Durban, South Africa.
Kubashni WoeberHIV Prevention Research Unit (HPRU), South African Medical Research Council (SAMRC), Durban, South Africa.
Neetha S MorarHIV Prevention Research Unit (HPRU), South African Medical Research Council (SAMRC), Durban, South Africa.
Nitesha JeenarainHIV Prevention Research Unit (HPRU), South African Medical Research Council (SAMRC), Durban, South Africa.
Zakir GaffoorHIV Prevention Research Unit (HPRU), South African Medical Research Council (SAMRC), Durban, South Africa.
Daniel K GondweCollege of Medicine - Johns Hopkins Bloomberg School of Public Health, Blantyre, Malawi.
Yvonne MakalaUniversity of North Carolina Project, Lilongwe, Malawi.
Llewellyn FleursDesmond Tutu HIV Foundation, Emavundleni Clinical Research Site, Cape Town, South Africa.
Krishnaveni ReddyWits Reproductive Health and HIV Institute (Wits RHI), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Thesla Palanee-PhillipsWits Reproductive Health and HIV Institute (Wits RHI), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Jared M BaetenDepartments of Global Health, Medicine, and Epidemiology, University of Washington, Seattle, WA, USA.
Ariane van der StratenWomen's Global Health Imperative (WGHI) RTI International, Berkeley, CA, USA; ASTRA Consulting, Kensington, CA, USA.
Lydia Soto-TorresNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Kristine TorjesenGlobal Health Population and Nutrition, FHI, Durham, NC, 360, USA.
South African Medical Research Council · ZAFamily Health International 360 · USMUJHU Research Collaboration · UGUniversity of the Witwatersrand · ZACentre for the AIDS Programme of Research in South Africa · ZADesmond Tutu HIV Foundation · ZANational Institute of Allergy and Infectious Diseases · USPopulation Services International · USRTI International · USUniversity of California, San Francisco · USUniversity of Malawi · MWUniversity of Washington · USUniversity of Zimbabwe · ZW

Funding

Microbicide Trials NetworkUM1AI068633 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI HILLIER, SHARON L. · 2011 to 2021
$175.0M
UZ-UCSF CTUUM1AI069436 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ZVAVAHERA MIKE CHIRENJE, LYNDA STRANIX-CHIBANDA · 2012 to 2026
$75.9M
Statistical and Data Management Center (SDMC): Microbicide Trials NetworkUM1AI068615 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BROWN, ELIZABETH RENATA · 2011 to 2021
$66.5M
Ujima Mentoring ProgramP30MH062246 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 2001 to 2026
$57.4M
WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Immaculate Lillian Nankya · 1994 to 2026
$50.0M
UZ-UCSF Clinical Trials UnitU01AI069436 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHIRENJE, ZVAVAHERA MIKE · 2007 to 2011
$49.3M
University of KwaZulu-Natal - CAPRISA HIV/AIDS Clinical Trials UnitUM1AI069469 · NIAID · UNIVERSITY OF KWAZULU-NATAL · PI QUARRAISHA ABDOOL KARIM · 2012 to 2026
$36.4M
Laboratory Center (LC): Microbicide Trials NetworkUM1AI106707 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI MELLORS, JOHN W, ROHAN, LISA CENCIA · 2014 to 2021
$27.1M
NIAID NIH HHS P30 AI036219NIAID NIH HHS U01 AI069436NIAID NIH HHS UM1 AI068615NIAID NIH HHS UM1 AI068633NIAID NIH HHS UM1 AI069436NIAID NIH HHS UM1 AI069469NIAID NIH HHS UM1 AI106707NIMH NIH HHS P30 MH062246
6 · The paper itself

Abstract

backgroundLow adherence to investigational products can negatively impact study outcomes, limiting the ability to demonstrate efficacy. To continue advancing potential new HIV prevention technologies, efforts are needed to improve adherence among study participants. In MTN-020/ASPIRE, a phase III randomized, double-blind, placebo-controlled study of the dapivirine vaginal ring carried out across 15 sites in sub-Saharan Africa, a multifaceted approach to adherence support was implemented, including a strong focus on participant engagement activities (PEAs). In this manuscript, we describe PEAs and participant attendance, and analyze the potential impact of PEAs on ring use.

methodsAll sites implemented PEAs and submitted activity and attendance reports to the study management team throughout the study. Participant demographics were collected via case report forms. Residual dapivirine remaining in the last ring returned by each participant was used to estimate drug released from the ring, which was then adjusted for time participants had the ring to calculate probable use categorized into three levels (low/intermittent/high). Product use was connected to PEA attendance using participant identification numbers. We used multivariate Poisson regression with robust standard errors to explore differences in ring use between PEA attendance groups and reviewed qualitative reports for illustrative quotes highlighting participant experiences with PEAs.

results2312 of 2629 study participants attended at least one of 389 PEAs conducted across sites. Participant country and partner knowledge of study participation were most strongly associated with PEA attendance (p < 0.005) with age, education, and income status also associated with event attendance (p < 0.05). When controlling for these variables, participants who attended at least one event were more likely to return a last ring showing at least some use (RR = 1.40) than those who never attended an event. There was a stronger correlation between a last returned ring showing use and participant attendance at multiple events (RR = 1.52).

conclusionsOur analysis supports the growing body of work illustrating the importance of meaningfully engaging research participants to achieve study success and aligns with other analyses of adherence support efforts during ASPIRE. While causation between PEA attendance and product use cannot be established, residual drug levels in returned rings strongly correlated with participant attendance at PEAs, and the benefits of incorporating PEAs should be considered when designing future studies of investigational products.

Indexed as

Anti-HIV AgentsContraceptive Devices, FemaleHIV InfectionsFemaleHumansPyrimidinesAnti-HIV AgentsDapivirinePyrimidinesAdherenceDapivirineHIV preventionMicrobicidesParticipant engagementPrEPRing

Identifiers

PMID34749675
PMCPMC8576984
OpenAlexW3211491939

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.